Beryllium

What is Beryllium?

OSHA’s beryllium standard, 29 CFR 1910.1024(k)(3)(ii)(E), requires employers to offer a blood test measuring immune reaction to the metal. No other OSHA substance-specific health standard is built around an antigen-specific immune assay, and that one fact explains most of what makes element 4 unusual. Beryllium is not a classical poison the way lead or arsenic are. It is a sensitizer with a genetic entry requirement, and in the people it harms, the immune system does the harming.

Beryllium is atomic number 4, atomic weight 9.0122, with a single stable isotope, beryllium-9. ATSDR’s 2023 toxicological profile describes it as the lightest nonreactive metal, and its stiffness-to-weight ratio is why it ends up in aerospace structures, X-ray windows, and precision instruments. Commercially it comes from two minerals. Beryl, formula Be3Al2Si6O18, runs up to 5 percent beryllium by weight and is the same mineral species as emerald and aquamarine. Bertrandite, Be4Si2O7(OH)2, runs roughly 15 percent. The US Geological Survey reports that the open-pit bertrandite operation at Spor Mountain in Juab County, Utah is the only known economic deposit of its type, that Materion is the sole domestic ore producer, and that US mine shipments in 2015 contained about 205 metric tons, an estimated 90 percent of world production. Apparent domestic consumption that year was 233 metric tons. Of Materion’s value-added sales in 2015, 21 percent went into industrial components, 18 percent into consumer electronics, 15 percent into automotive electronics, and 9 percent into defense.

None of that belongs in a supplement bottle, and beryllium is not a nutrient by any regulatory or biochemical definition. FDA’s 2022 substances-added-to-food inventory does not list it. It reaches consumers two ways: as a trace contaminant carried in from soil and rock by botanical and mineral raw materials, and, in one small corner of the market, as a labeled homeopathic ingredient.

Primary Functions & Benefits

Beryllium has no function to describe, so this section covers its mechanism of injury instead, which for a metal is unusually well mapped, down to the atomic structure.

The injury is immunologic. Inhaled beryllium that reaches the lung is taken up by antigen-presenting cells, and in susceptible people it becomes part of a T cell ligand. Clayton and colleagues published the structure in Cell in 2014, volume 158, pages 132 to 142. A Be2+ cation becomes buried inside an HLA-DP2 and self-peptide complex, coordinated by acidic amino acids contributed by both the MHC molecule and the peptide. The T cell receptor never touches the beryllium ion. It reads the surface distortion that the firmly bound Be2+ and an accompanying Na+ cation create in a self-structure the immune system previously tolerated. The authors place chronic beryllium disease on the border between allergic hypersensitivity and autoimmunity, a fair description of a disease whose antigen is an element with 4 protons.

Fontenot and colleagues had shown the binding directly in 2006 in the Journal of Immunology, volume 177, pages 3874 to 3883, using 9Be nuclear magnetic resonance. Beryllium bound their recombinant HLA-DP2 construct and did not bind HLA-DP4, which differs by 4 amino acid residues. Presentation did not require antigen processing, since fixed antigen-presenting cells pulsed with beryllium sulfate still drove T cell proliferation.

The downstream result is a CD4-positive, Th1-polarized response that accumulates beryllium-specific T cells in the lung and organizes them into noncaseating granulomas. There is no competing beneficial pathway, no threshold below which a favorable effect appears, and no tissue where beryllium substitutes usefully for anything.

Forms & Standardization

Standardization here means chemical speciation for hazard classification, not potency, because the toxicology of beryllium is driven by physical form rather than by elemental mass.

ATSDR’s 2023 profile states that distribution in the body depends on the form and solubility of the compound and on its particle size. Three variables do most of the work:

• Solubility. Soluble salts, chiefly beryllium sulfate, fluoride, chloride, and oxyfluoride, dissolve in airway lining fluid and produce the acute chemical pneumonitis described by VanOrdstrand and colleagues in 1945. Eisenbud and colleagues in 1948 placed acute disease above 0.1 milligram per cubic meter, which is 100 micrograms, or 500 times the current OSHA limit.

• Particle size. Airborne beryllium is particulate matter, and deposition depends on aerodynamic diameter. The respirable fraction reaches the alveoli where antigen presentation happens. This is why ACGIH’s threshold limit value is written for the inhalable fraction and why OSHA regulates dust, fume, and mist rather than bulk metal.

• Calcination history. Beryllium oxide fired at 1,000 degrees Celsius behaved very differently from oxide fired at 500 degrees in beagle dogs: 62 percent of the high-fired material was still in the lungs at 180 days, against 17 percent of the low-fired. Two samples with identical elemental assays can carry different lung burdens.

The forms encountered in practice are beryllium metal, beryllium oxide ceramic, copper-beryllium and nickel-beryllium alloys, and beryl and bertrandite ore. Ore behaves differently from processed material. Deubner and colleagues in 2001 studied miners exposed to naturally occurring bertrandite and found no increased risk of chronic beryllium disease, one of the few reassuring findings here and one reason mineral-sourced supplement contamination is a different question from factory air.

For labeling purposes, IARC classifies beryllium and beryllium compounds together as a single Group 1 entry. The agency does not carve out a safer species.

Food Sources

This section is routes of exposure, and the distinction between what you breathe and what you swallow is the most important line in the whole issue.

Inhalation. This is the route that causes disease. Ambient US air typically runs below 0.2 nanograms per cubic meter as an annual average, per EPA 2022 data cited by ATSDR, with a general range of 0.03 to 0.2. Sax and colleagues measured 0.0015 nanograms indoors in New York City and 0.0018 in Los Angeles in 2006. Compare that to the OSHA limit of 200 nanograms per cubic meter, and to the 0.04 micrograms, or 40 nanograms, at which Schuler and colleagues in 2012 observed the lowest sensitization signal. Community air runs roughly 200 to 1,000 times below the lowest observed effect level. Coal and fuel oil combustion, windblown dust, and volcanic particles are the sources.

Ingestion. This is the route that does not cause the classic disease. EPA estimates daily beryllium intake from US food at 0.12 micrograms. Other figures disagree sharply: Muto and colleagues reported 84.4 micrograms per day in Japanese hospital diets in 1994, and IARC’s Volume 100C cites a range of 5 to 100 from an older survey. The spread reflects analytical difficulty at trace levels more than real dietary variation. Drinking water averages roughly 0.19 micrograms per liter, on the order of 1 microgram per day. Foods range from under 0.1 to 2,200 micrograms per kilogram fresh weight, with kidney beans, crisp bread, and garden peas at the high end.

Gastrointestinal absorption is negligible, and the reason is chemical. Furchner and colleagues in 1973 recovered 0.11, 0.24, 0.38, and 3.71 percent of an oral radiolabeled dose in the urine of rats, mice, dogs, and monkeys respectively, with 98 to 108 percent in feces. Reeves showed in 1965 that beryllium precipitates as insoluble phosphate in the alkaline small intestine, which caps absorption regardless of how much is swallowed.

Dermal. Poorly absorbed, but not harmless. Soluble beryllium compounds can sensitize through skin, and ACGIH carries both dermal sensitizer and skin notations for them. VanOrdstrand’s 1945 series described ulcers forming where skin had been abraded, predominantly among beryllium sulfate workers.

Who Should Take Beryllium

No one should take beryllium, and there is no population, condition, age group, or clinical scenario in which supplemental intake is appropriate. This section is about who is already exposed and who should ask for a test.

OSHA estimated that its 2017 rule covers about 62,000 US workers. The agency and ATSDR identify these settings:

• Beryllium extraction, smelting, alloy production, machining, and grinding

• Beryllium oxide ceramics manufacturing

• Dental laboratory work involving nickel-beryllium alloys

• Nuclear weapons and research facilities, covered separately under DOE’s 10 CFR Part 850

• Abrasive blasting in construction and shipyards, covered by the January 2017 rule, with those standards amended by the final rule of August 31, 2020

• Coal-fired power generation and coal ash handling

• Bystander exposure, including office staff at beryllium plants and family members handling contaminated work clothing

That last category is the one most often missed. The National Research Council’s 2008 review documented sensitization and disease in secretaries, security guards, end-product inspectors, workers hired years after beryllium operations ceased, and household contacts. Newman and Kreiss in 1992 and Eisenbud and Lisson in 1983 described cases such as a secretary from a fluorescent lamp plant and the wife of an extraction worker.

Who should consider testing: anyone with the exposure history above, and anyone carrying a sarcoidosis diagnosis who has worked near machined metal, ceramics, dental alloys, or nuclear facilities. The test is the beryllium lymphocyte proliferation test, and Section 20 covers what a result means. For former Department of Energy workers, an abnormal BeLPT or BeLTT on blood or lavage cells establishes beryllium sensitivity as a covered illness under EEOICPA Part B, which provides medical monitoring only; the $150,000 lump sum plus medical benefits attaches once the condition has progressed to chronic beryllium disease.

Who Should AVOID or Use Caution

Avoidance is universal, so the useful question is who faces elevated consequences from the same air everyone else is breathing.

Carriers of HLA-DPB1 Glu69. Van Dyke and colleagues studied 386 workers at a US nuclear weapons facility in 2011: 70 sensitized, 61 with chronic beryllium disease, 255 controls. Any Glu69 carriage raised the odds of disease 7.61-fold, 95 percent confidence interval 3.66 to 15.84. Allele identity mattered more than mere carriage. A single Glu69-positive 02 allele carried odds of 12.01 for sensitization and 3.46 for disease. A single non-02 Glu69 allele carried 29.54 and 11.97. Two copies carried 55.68 and 22.54.

Carriers of the less common Glu69 alleles. Wang and colleagues in 1999 sequenced haplotypes precisely and found the common 0201 allele accounted for 68 percent of Glu69 carriers among exposed controls, while 84 percent of Glu69-carrying disease cases had a non-0201 allele. The rare alleles 1701, 0901, and *1001 appeared in 50 percent of the disease group against 6.7 percent of controls.

Glu69-negative people are not exempt. Sato and colleagues reported in Tissue Antigens in 2007 on 88 disease cases, 86 sensitized, and 173 exposed controls. Among Glu69-negative subjects, HLA-DRB1*13 appeared in 70 percent of disease cases against 16 percent of exposed controls, and BTNL2 rs3117099 TT homozygosity in 40 percent against 2.9 percent.

People already diagnosed with sarcoidosis. See Section 19.

Nobody should be genotyped as a substitute for exposure control, and no carrier status makes an exposure acceptable. ATSDR built the genetic point into its risk assessment: the chronic inhalation minimal risk level of 0.001 micrograms per cubic meter uses a total uncertainty factor of 30, of which a factor of 3 is assigned specifically to the genetically susceptible subpopulation.

Recommended Dosages

There is no recommended dosage for beryllium at any level, by any route, for any purpose, and no number below should be read as an amount to consume. What follows are ceilings, meaning concentrations that agencies have set as limits on unavoidable exposure.

Occupational air limits.

• OSHA permissible exposure limit: 0.2 micrograms per cubic meter as an 8-hour time-weighted average, 29 CFR 1910.1024(c)(1)

• OSHA short-term exposure limit: 2.0 micrograms per cubic meter over a 15-minute sampling period, 1910.1024(c)(2)

• OSHA action level: 0.1 micrograms per cubic meter as an 8-hour TWA, triggering exposure assessment and, above 30 days of exposure per year, medical surveillance

• NIOSH recommended exposure limit: 0.5 micrograms per cubic meter as a 10-hour TWA

• ACGIH threshold limit value: 0.05 micrograms per cubic meter as an 8-hour TWA for the inhalable particulate fraction, carrying an A1 confirmed human carcinogen designation, a respiratory sensitizer notation, and dermal sensitizer and skin notations for soluble compounds

• DOE action level under 10 CFR 850.23: no greater than 0.2 micrograms per cubic meter as an 8-hour TWA, with surface release criteria under 850.31 of 0.2 micrograms per 100 square centimeters removable for public release and 3 micrograms for transfer between beryllium facilities

Environmental and health-based values.

• EPA maximum contaminant level and MCL goal for drinking water: 0.004 milligrams per liter, or 4 micrograms per liter, matched by FDA’s bottled water allowance

• EPA oral reference dose: 0.002 milligrams per kilogram per day, IRIS 1998, which works out to 140 micrograms per day for a 70-kilogram adult

• EPA inhalation reference concentration: 0.00002 milligrams per cubic meter

• ATSDR chronic-duration inhalation minimal risk level: 0.001 micrograms per cubic meter

• California Proposition 65 no significant risk levels: 0.1 micrograms per day for beryllium and for beryllium oxide, and 0.0002 micrograms per day for beryllium sulfate

Two of those deserve a note. The oral reference dose of 140 micrograms per day is a bound on incidental ingestion rather than a target, and it sits that high because absorption is under 1 percent. The Proposition 65 figure for beryllium sulfate is roughly 700,000 times smaller, because it is a cancer-based value for a soluble species rather than a noncancer value for the element.

Timing & Administration

There is no administration schedule for a substance nobody should be administering, and the only timing that matters is how quickly an exposed worker gets tested, which OSHA sets at the first medical examination and at least every 2 years thereafter.

Timeline of Effects

Beryllium runs on two clocks, and neither resembles the onset curve of a nutrient.

Sensitization: immediate and permanent. Sensitization is an immunologic event, not a cumulative burden. It can follow brief or incidental exposure, and once established it does not reverse. The National Research Council’s 2008 review documented disease in a shipper and receiver of 22 years at a facility where the median of 393 full-shift personal samples was 0.03 micrograms per cubic meter, below OSHA’s action level of 0.1. Henneberger and colleagues in 2001 found disease in 1.4 percent of short-term ceramics workers against 9.1 percent of long-term workers, so duration matters at the group level and does not protect the individual.

Disease: months to decades. StatPearls gives a latency between exposure and symptom onset of 3 months to 30 years. Newman and colleagues, in the American Journal of Respiratory and Critical Care Medicine in 2005, volume 171, pages 54 to 60, followed 55 sensitized individuals with repeat bronchoalveolar lavage and transbronchial biopsy. Disease developed in 17, or 31 percent, over an average 3.8 years, range 1.0 to 9.5. The remaining 38, or 69 percent, stayed sensitized without disease over an average 4.8 years, range 1.7 to 11.6. The authors estimated progression at 6 to 8 percent per year. Roughly 50 percent of sensitized people already have granulomas at first clinical evaluation, so the sensitized-only group is partly a group that has not been biopsied yet.

Acute disease: days to weeks. ATSDR describes acute beryllium disease as developing over several weeks after short-term inhalation of high concentrations of soluble compounds. Cummings and colleagues identified 2 such cases in metal production workers in the early 1980s, with facility air samples never exceeding 100 micrograms per cubic meter and most below 10.

Benefits of Taking Beryllium

There are no benefits, none have ever been demonstrated in any species, and no clinical trial of beryllium administration exists in any indication. What this section can honestly cover is the industrial history, told as history.

Beryllium’s usefulness was always structural and electronic, never biological. Its defining moment in public health came from fluorescent lighting. Zinc beryllium silicate was an early lamp phosphor, and Hardy and Tabershaw described the resulting syndrome in 1946 in 17 chronically exposed workers at a lamp plant, who developed anorexia, dyspnea, cough, fatigue, and weakness. An autopsy on one showed increased lung weight, diffuse fibrosis, granulomas, and abnormal bronchiolar lining, plus right atrial and ventricular hypertrophy, the cardiac consequence of a fibrotic lung. Six of the women among the 17 died of pulmonary or cardiovascular disease. The American Industrial Hygiene Association Quarterly announced in 1949, in volume 10, that major manufacturers would discontinue the beryllium phosphor. Halophosphates replaced it, and modern lamps use rare earth triphosphors.

The Beryllium Case Registry followed. Hardy, Rabe, and Lorch described its methods for 1952 to 1966 in the Journal of Occupational Medicine, volume 9, pages 271 to 276. Administered at Massachusetts General Hospital, it became the backbone of the early epidemiology. Freiman and Hardy published its largest histopathology study in 1970, covering 130 cases, and Steenland and Ward analyzed 689 registry entrants in 1991, finding a lung cancer standardized mortality ratio of 2.00, 95 percent confidence interval 1.33 to 2.89, on 28 deaths. Kidney stones turned up in 10 percent of registry disease cases. The record also includes 93 cases of acute beryllium pneumonitis at 2 refineries before 1950, with 10 deaths, reported by the American College of Chest Physicians in 1965.

Potential Negatives & Side Effects

“Side effects” implies a main effect, and beryllium has none, so this section describes the adverse effect profile in full.

Beryllium sensitization. An immune response with no symptoms, no illness, and no disability, defined at 29 CFR 1910.1024(b). It is not benign, because it is the gateway state and it is permanent.

Chronic beryllium disease. A granulomatous lung disease in a sensitized person. Presentation is dyspnea on exertion, dry cough, fatigue, and weight loss, with restrictive or mixed physiology and reduced diffusing capacity. Radiographs can be normal early. StatPearls reports mortality across published series from 5 to 38 percent.

Acute beryllium disease. Chemical pneumonitis from soluble compounds at high concentration, with nasal and pharyngeal irritation, sore throat, weight loss, labored breathing, and reduced vital capacity.

Lung cancer. Covered in Section 14.

Skin. Contact dermatitis, skin granulomas, and ulceration. VanOrdstrand’s 1945 series found ulcers formed at abraded sites and began as small indurated papules. Biopsied skin granulomas showed the same histology as the lung lesions.

Systemic and extrapulmonary. Granulomas have been described in liver, spleen, lymph nodes, and skin. Cor pulmonale develops in advanced disease. Hardy and Tabershaw reported hepatic necrosis in one fluorescent lamp worker.

There is no reduce-or-stop threshold to offer, because there is no intentional intake to titrate. The clinical equivalent is removal from exposure, and even that does not clear the lung. Verma and colleagues in 2003 recovered beryllium from the lungs of a man years after exposure ended, who had worked with beryllium powder and dust for about 6 years in a light bulb factory.

Deficiency Symptoms

No beryllium deficiency exists, has ever been described, or is biologically possible, because there is no beryllium-dependent enzyme, transporter, or structural protein in any organism studied.

The contrast with a genuine trace element shows what a real essentiality claim requires. Molybdenum has an adult recommended dietary allowance of 45 micrograms per day, set by the Institute of Medicine in 2001, and identified human enzymes that require it, including sulfite oxidase and xanthine oxidase. Deficiency has been documented clinically in a single TPN patient on long-term parenteral nutrition, with symptoms that corrected with repletion. Selenium has an adult RDA of 55 micrograms per day, at least 25 identified human selenoproteins, and a named deficiency disease. Each of those four elements of proof exists for molybdenum and selenium and none exists for beryllium.

Beryllium does produce one deficiency, and it is somebody else’s. Rats fed large amounts of beryllium carbonate develop rickets, reported across studies from 1933 to 1951 at doses of 35 to 840 milligrams per kilogram per day. ATSDR notes the rickets are not a direct effect on bone. Kay and Skill hypothesized in 1934 that beryllium precipitates dietary phosphorus in the acidic stomach, producing phosphorus deficiency. Swallowed beryllium does not create a beryllium requirement, it interferes with an actual nutrient.

Toxicity Symptoms

Toxicity from beryllium follows the route, and inhalation accounts for essentially all documented human disease.

Carcinogenicity. IARC classifies beryllium and beryllium compounds in Group 1, carcinogenic to humans, most recently in Volume 100C, published 2012, after earlier evaluations in 1971, 1979, 1987, and 1993. The cancer site with sufficient evidence is the lung. Ward and colleagues in 1992 followed 9,225 workers at 7 US processing plants and found a lung cancer standardized mortality ratio of 1.26, 95 percent confidence interval 1.12 to 1.42, highest at the oldest facilities. Sanderson and colleagues in 2001 and Schubauer-Berigan and colleagues in 2008 ran a nested case-control study at a single plant with 142 lung cancer cases and found positive exposure-response using 10-year lagged average exposure. The National Toxicology Program lists beryllium as a known human carcinogen, EPA’s IRIS called inhaled beryllium a probable human carcinogen in 1998, and California listed it under Proposition 65 on October 1, 1987.

Respiratory. Granulomatous inflammation, interstitial fibrosis, restrictive physiology, impaired gas exchange, and eventually cor pulmonale. Pappas and Newman in 1993 found one or more lung function abnormalities in 93 percent of 15 clinically identified cases against 57 percent of 21 surveillance-identified cases, which shows how much disease surveillance catches before symptoms.

Oral toxicity in animals. High-dose oral beryllium produces ulcerative and inflammatory lesions of the stomach, small intestine, and large intestine in dogs and rodents, plus the rickets described above, at milligram-per-kilogram doses far above any conceivable dietary exposure. ATSDR states that oral data are inadequate to assess carcinogenic potential.

What toxicity does not look like. There is no acute oral poisoning syndrome in humans at environmentally realistic doses, no neurologic syndrome comparable to lead, and no chelation protocol. Absorbed beryllium accumulates short-term in liver and long-term in lymph nodes and bone, with a skeletal half-life WHO puts at about 450 days. Krachler and colleagues in 1999 found evidence of placental transfer and breast milk excretion, a real finding and not a dosing concern, since maternal intake is on the order of tenths of a microgram per day.

How Beryllium Works

The word “works” is doing no favorable work here, and this section describes the two mechanisms by which beryllium acts on biological systems, one immunologic and one enzymatic.

The immunologic mechanism is the one that matters clinically and is described in Section 3. Be2+ inserts into an HLA-DP2 and self-peptide complex, distorting a tolerated self-structure into a novel T cell epitope. The reason position 69 controls susceptibility is chemical rather than statistical: a glutamic acid there supplies one of the acidic coordination sites the beryllium ion requires. Substitute a different residue and the metal has nowhere to bind, which is what Fontenot’s group observed when HLA-DP4, differing by 4 residues, failed to bind beryllium at all. The result is a self-sustaining CD4 T cell response that recruits macrophages and organizes noncaseating granulomas identical in appearance to those of sarcoidosis, which is the whole diagnostic problem.

The enzymatic mechanism is older science and explains the animal findings. Be2+ has the smallest ionic radius of any divalent metal cation and competes at magnesium-binding sites. Klemperer, Miller, and Hill described the inhibition of alkaline phosphatase by beryllium in the Journal of Biological Chemistry in 1949, volume 180, pages 281 to 288. DuBois, Cochran, and Mazur reported inhibition of phosphatases by beryllium and its antagonism by manganese in Science the same year, volume 110, page 420. Luke and colleagues in 1975 proposed that beryllium reduces replication fidelity by mimicking magnesium and impairing polymerase editing, and Snow developed that line in 1992. An intramuscular injection study in rats reported alkaline phosphatase reductions of 29 to 48 percent.

Note what the second mechanism does not do. It is not the pathway to chronic beryllium disease, it requires systemic concentrations oral exposure cannot deliver at absorption under 1 percent, and it has no bearing on what is in a capsule. It is included because it is the mechanism people reach for when arguing that beryllium has a biological role. Enzyme inhibition is a chemical property, not a physiological function.

Synergistic Supplements

Nothing is synergistic with a carcinogenic sensitizer, and the only combination worth naming is negative, since manganese was shown to antagonize beryllium’s phosphatase inhibition in vitro in 1949 with no demonstrated relevance to human disease.

Interactions & What NOT to Take

There is no intake to interact with, so the practical interactions are between beryllium exposure and other lung insults, and between beryllium disease and its own treatment.

Smoking. Tobacco smoke is an independent lung carcinogen, and the cohorts that established beryllium’s lung cancer risk had to adjust for it. Newman’s 2005 progression cohort found no difference in smoking status between progressors and non-progressors, so smoking is not established as a progression driver, but it remains the largest modifiable competing risk in the same organ.

Other granulomatous exposures. Co-occurring exposures to silica, hard metals such as cobalt-tungsten, and aluminum can produce granulomatous lung disease that muddies an already difficult differential.

Corticosteroids and immunosuppressants. Treatment for chronic beryllium disease is corticosteroids first line, usually at a high starting dose and often for several months before symptoms respond, with methotrexate at 7.5 milligrams weekly plus 1 milligram of folic acid, or azathioprine, for steroid-resistant cases. Monitoring runs every 8 to 12 weeks. There is no cure and no agent that clears retained beryllium.

Chelators. No chelation therapy is established for beryllium. Anyone offering one for a positive BeLPT is selling a treatment for an immune state that chelation does not address.

Quality, Testing & Adulteration

This is where a toxic element intersects with the supplement aisle, and the finding is a gap in test scope rather than a contamination scandal.

What standard heavy metal panels cover. USP General Chapter 2232, Elemental Contaminants in Dietary Supplements, sets permitted daily exposures for inorganic arsenic at 15 micrograms per day, cadmium at 5, lead at 10, total mercury at 15, and methylmercury at 2, with component limits of 1.5, 0.5, 1.0, 1.5, and 0.2 micrograms per gram. The chapter states its focus is the four major elements of toxicological concern. USP General Chapter 232, which applies to drug products and follows ICH Q3D, covers a longer list including chromium, copper, molybdenum, nickel, vanadium, palladium, and platinum. Beryllium appears in neither. ConsumerLab’s published methods specify ICP-MS testing for lead, arsenic, cadmium, and mercury, and beryllium is not among the analytes.

So “tested for heavy metals” on a bottle, and the certificate behind it, almost always means those 4 elements. A beryllium result is not being suppressed. It is not being generated.

Whether that gap matters. Less than the scope gap might suggest. Kenny and colleagues published a metallomic survey of botanical ingredients in Scientific Reports in 2022, analyzing 30 plant species across 50 samples for 22 elements by high-resolution ICP sector field mass spectrometry, beryllium included. It ranged from 3 to 121 micrograms per kilogram. At the top of that range, a generous 5-gram daily dose delivers about 0.6 micrograms, against an oral reference dose equivalent to roughly 140 micrograms per day, with absorption under 1 percent. The same study flagged cadmium in 16 percent of samples and lead in 8 percent at high intake, which indicates where testing effort belongs.

What to actually ask for. If a beryllium number matters to you, for example because you have a positive BeLPT, request the full ICP-MS element list rather than the summary, since the instrument measures beryllium at mass 9 routinely and the result is often acquired and simply not reported. Ask whether the panel is USP 2232 scope or a broader in-house method, and ask for results per gram of finished product rather than per serving.

Where trace element risk is real. Mineral-heavy products carry the highest burden: clay and bentonite products, sea mineral concentrates, trace mineral drops, and humic and fulvic acid preparations. Scrutinize those on lead and arsenic grounds first.

Special Considerations

The sarcoidosis problem. Chronic beryllium disease and sarcoidosis are histologically indistinguishable, and this is the most consequential clinical fact in this issue. Müller-Quernheim and colleagues published in the European Respiratory Journal in 2006, volume 27, pages 1190 to 1195. Among 84 patients seen for diagnosis or re-evaluation of sarcoidosis in whom beryllium exposure was recognized, the diagnosis was corrected to chronic beryllium disease in 34, or 40 percent. The lag between the two diagnoses ranged from 0 to 18 years, median 3, and mean age at correct diagnosis was 43.9 years, range 25 to 80. That cohort was selected for possible exposure, so 40 percent is not a general reclassification rate. StatPearls puts the broader estimate near 6 percent of all sarcoidosis diagnoses. Even 6 percent of a common diagnosis is a lot of people, and the difference matters: chronic beryllium disease is compensable, traces to an identifiable workplace, and implies coworkers who should be tested.

Pregnancy and children. Krachler and colleagues documented placental transfer and breast milk excretion in 1999. Nogaj and colleagues in 2014 measured beryllium in the pharyngeal tonsils of 379 Polish children aged 2 to 17, finding a mean of 16 nanograms per gram, range 1 to 58, higher in girls than boys. These are background findings, not exposures to act on. ATSDR notes that pediatric data are limited and that the animal effect of concern from ingestion is phosphorus-mediated rickets.

Dental work. Nickel-beryllium alloys have been used in crowns and partial dentures, and Tai and colleagues in 1992 measured release of 8 micrograms per day per crown in an artificial oral environment. The larger concern is the dental technician grinding the alloy rather than the patient wearing it.

Beryllium in homeopathic products. Beryllium metallicum is sold in the United States as a homeopathic pellet. DailyMed lists a 30C product from Washington Homeopathic Products under NDC 68428-896, marketing category “unapproved homeopathic,” labeled purpose “to relieve the symptoms of dry cough.” Boiron markets 30C and 200C versions for the same indication. A 30C preparation is a 1-in-100 dilution repeated 30 times, or 10 to the minus 60, roughly 36 orders of magnitude past Avogadro’s number of 6.022 times 10 to the 23rd. There is essentially nothing in the pellet, which is the only reason this is not a hazard. FDA withdrew Compliance Policy Guide 400.400 on October 25, 2019, removing the enforcement framework these products were marketed under. A cough product sharing a name with the cause of a granulomatous lung disease is an unhelpful thing to have on a shelf.

Research Status & Evidence Quality

The evidence base for beryllium is strong on mechanism and disease and weak exactly where a supplement consumer would want it strong.

What is well established. The structural immunology is solved to the level of crystal structures. The genetic association has been replicated repeatedly, including in McCanlies and colleagues’ population-based cohort of 884 beryllium workers in the American Journal of Industrial Medicine in 2004, which found odds ratios of 9.4, 95 percent confidence interval 5.4 to 16.6, for disease and 3.3, interval 1.9 to 5.9, for sensitization, homozygotes overrepresented in both at p less than 0.001. Prevalence is well characterized too: Kreiss and colleagues’ 2007 review of 12 studies found disease prevalence from 0.1 percent to nearly 8 percent, and Rosenman and colleagues in 2005 found 7.0 percent sensitization and 7.6 percent definite or probable disease among 577 former workers.

What the BeLPT actually tells you. This is the most misread result in the field. Stange and colleagues tested 12,194 current and former Department of Energy employees across 18 sites at 4 laboratories and published in 2004. Sensitivity was 0.683 and specificity 0.969, which sounds good until you apply it. The positive predictive value of a single abnormal test was 0.253. False positives ran 1.09 percent overall, laboratory range 0.00 to 3.35 percent. Split samples sent between laboratories produced a false negative rate of 31.7 percent, while repeatability within a laboratory was 80.4 to 91.9 percent. Middleton and colleagues in 2008 calculated that requiring confirmation of an abnormal result raises the positive predictive value substantially and reduces false positives, and that a single unconfirmed abnormal is usually insufficient to establish sensitization in an apparently healthy person.

That is why OSHA defines “confirmed positive” as 2 abnormal results, or one abnormal and one borderline, or 3 borderline, within 3 years. A single abnormal BeLPT is a reason for a second test, not a diagnosis. A confirmed positive establishes sensitization, not disease: Deubner and colleagues found it predicted disease 45 percent of the time. A normal BeLPT in a genuinely exposed person is not a clean bill of health either, given that 31.7 percent false negative rate.

What is missing. There is no evidence base on oral beryllium in humans at any dose, no clinically actionable biomarker of low-level environmental body burden, and no supplement supply chain surveillance comparable to the arsenic and lead work of the last 15 years. Kenny’s 2022 survey is one of very few datasets reporting beryllium in plant ingredients at all.

Summary & Key Takeaways

• Beryllium is element 4, an industrial metal with no nutritional role, placed by IARC in Group 1 as carcinogenic to humans in Volume 100C, 2012, with lung as the target site.

• The disease is immunologic. Be2+ buries itself in an HLA-DP2 and self-peptide complex and creates a new T cell epitope, which Clayton and colleagues solved structurally in Cell in 2014.

• Susceptibility is genetic. HLA-DPB1 Glu69 carriage runs 30 to 47 percent in controls, 39 to 90 percent in the sensitized, and 73 to 97 percent in the diseased. Two Glu69 copies raised the odds of sensitization 55.68-fold in Van Dyke’s 2011 study of 386 nuclear workers.

• OSHA cut the permissible exposure limit tenfold on January 9, 2017, from 2.0 to 0.2 micrograms per cubic meter as an 8-hour TWA, with a 2.0 microgram 15-minute short-term limit and a 0.1 microgram action level. The rule took effect May 20, 2017 and covers about 62,000 workers.

• Sensitization is permanent and can follow incidental exposure. Progression to disease ran 31 percent over an average 3.8 years in Newman’s 55-person cohort, roughly 6 to 8 percent per year.

• A single abnormal BeLPT has a positive predictive value of about 0.25, which is why OSHA requires 2 abnormal results, or an abnormal and a borderline, or 3 borderline, within 3 years.

• Chronic beryllium disease is mistaken for sarcoidosis routinely. Müller-Quernheim reclassified 34 of 84 sarcoidosis patients, median diagnostic lag 3 years and maximum 18. Anyone with a sarcoidosis diagnosis plus a metalworking, ceramics, dental lab, or nuclear work history should ask about a BeLPT.

• Ingestion is not the route of concern. Absorption is under 1 percent because beryllium precipitates as insoluble phosphate in the alkaline intestine, and EPA estimates US dietary intake at 0.12 micrograms per day.

• Beryllium is not on standard supplement heavy metal panels. USP General Chapter 2232 covers arsenic, cadmium, lead, and mercury, and ConsumerLab reports those same four, so a “tested for heavy metals” claim carries no beryllium information.

• Measured levels in botanicals are low. Kenny’s 2022 survey of 30 plant species found 3 to 121 micrograms per kilogram, or roughly 0.6 micrograms per day at the high end and a 5-gram dose, against an oral reference dose equivalent to about 140.

• The one place beryllium appears deliberately on a US supplement shelf is homeopathic Beryllium metallicum at 30C and 200C, dilutions of 10 to the minus 60 and beyond, containing essentially none of it.

• Nothing here supports taking beryllium. The actionable items are occupational: know your exposure history, know that testing exists, and know that a sarcoidosis diagnosis in an exposed person deserves a second look.